MX2022013745A - Derivados de n-(piperidin-4-il)benzamida de accion luminal. - Google Patents
Derivados de n-(piperidin-4-il)benzamida de accion luminal.Info
- Publication number
- MX2022013745A MX2022013745A MX2022013745A MX2022013745A MX2022013745A MX 2022013745 A MX2022013745 A MX 2022013745A MX 2022013745 A MX2022013745 A MX 2022013745A MX 2022013745 A MX2022013745 A MX 2022013745A MX 2022013745 A MX2022013745 A MX 2022013745A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- luminally
- piperidin
- acting
- benzamide derivatives
- Prior art date
Links
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen compuestos de Fórmula 1, (ver Fórmula), y sales farmacéuticamente aceptables de los mismos, en donde m, R1, R2, R3, R4, R5, R6, X1, X2, X3 y X4 se definen en la descripción. Esta descripción también hace referencia a materiales y métodos para la preparación de compuestos de Fórmula 1, a composiciones farmacéuticas que los contienen y a su uso para el tratamiento de enfermedades, trastornos y afecciones asociados con el receptor 5-HT4.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063019829P | 2020-05-04 | 2020-05-04 | |
| PCT/US2021/030493 WO2021225968A1 (en) | 2020-05-04 | 2021-05-03 | Luminally-acting n-(piperidin-4-yl)benzamide derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022013745A true MX2022013745A (es) | 2022-11-16 |
Family
ID=76060006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022013745A MX2022013745A (es) | 2020-05-04 | 2021-05-03 | Derivados de n-(piperidin-4-il)benzamida de accion luminal. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230158010A1 (es) |
| EP (1) | EP4146625A1 (es) |
| JP (1) | JP2023525986A (es) |
| KR (1) | KR20230005893A (es) |
| CN (1) | CN115515933A (es) |
| AR (1) | AR122005A1 (es) |
| AU (1) | AU2021266690A1 (es) |
| BR (1) | BR112022022184A2 (es) |
| CA (1) | CA3182379A1 (es) |
| CL (1) | CL2022003067A1 (es) |
| CO (1) | CO2022015823A2 (es) |
| EC (1) | ECSP22091230A (es) |
| IL (1) | IL297456A (es) |
| MX (1) | MX2022013745A (es) |
| PE (1) | PE20231375A1 (es) |
| TW (1) | TW202208333A (es) |
| WO (1) | WO2021225968A1 (es) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| KR100976063B1 (ko) * | 2007-03-16 | 2010-08-17 | 동아제약주식회사 | 신규한 벤즈아미드 유도체 화합물 및 그의 제조방법 |
| KR20100026641A (ko) * | 2008-09-01 | 2010-03-10 | 동아제약주식회사 | 신규한 벤즈아미드 유도체 화합물 및 그의 제조방법 |
-
2021
- 2021-05-03 BR BR112022022184A patent/BR112022022184A2/pt unknown
- 2021-05-03 MX MX2022013745A patent/MX2022013745A/es unknown
- 2021-05-03 JP JP2022567186A patent/JP2023525986A/ja active Pending
- 2021-05-03 EP EP21727329.1A patent/EP4146625A1/en active Pending
- 2021-05-03 WO PCT/US2021/030493 patent/WO2021225968A1/en active Application Filing
- 2021-05-03 AU AU2021266690A patent/AU2021266690A1/en active Pending
- 2021-05-03 KR KR1020227040506A patent/KR20230005893A/ko active Search and Examination
- 2021-05-03 CA CA3182379A patent/CA3182379A1/en active Pending
- 2021-05-03 CN CN202180033067.3A patent/CN115515933A/zh active Pending
- 2021-05-03 IL IL297456A patent/IL297456A/en unknown
- 2021-05-03 US US17/923,183 patent/US20230158010A1/en active Pending
- 2021-05-03 PE PE2022002548A patent/PE20231375A1/es unknown
- 2021-05-04 AR ARP210101213A patent/AR122005A1/es unknown
- 2021-05-04 TW TW110116059A patent/TW202208333A/zh unknown
-
2022
- 2022-11-02 CO CONC2022/0015823A patent/CO2022015823A2/es unknown
- 2022-11-04 CL CL2022003067A patent/CL2022003067A1/es unknown
- 2022-11-28 EC ECSENADI202291230A patent/ECSP22091230A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2022015823A2 (es) | 2022-11-18 |
| PE20231375A1 (es) | 2023-09-07 |
| CL2022003067A1 (es) | 2023-07-14 |
| WO2021225968A1 (en) | 2021-11-11 |
| US20230158010A1 (en) | 2023-05-25 |
| BR112022022184A2 (pt) | 2023-01-17 |
| ECSP22091230A (es) | 2023-02-28 |
| KR20230005893A (ko) | 2023-01-10 |
| IL297456A (en) | 2022-12-01 |
| CN115515933A (zh) | 2022-12-23 |
| JP2023525986A (ja) | 2023-06-20 |
| AR122005A1 (es) | 2022-08-03 |
| EP4146625A1 (en) | 2023-03-15 |
| CA3182379A1 (en) | 2021-11-11 |
| TW202208333A (zh) | 2022-03-01 |
| AU2021266690A1 (en) | 2022-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20080670L (no) | Substituerte piperaziner som metabotrofiske glutamatreseptorantagonister | |
| CR20230310A (es) | Inhibidores de prmt5 | |
| NO20054206L (no) | Bifenylderivater | |
| DE602005016261D1 (de) | Substituierte arylaminderivate und verwendungsverfahren | |
| ATE455756T1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
| DE602006012725D1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
| TW200630361A (en) | Integrin antagonists useful as anticancer agents | |
| NO20084603L (no) | Dialkylfenylforbindelser som har beta2 adrenergisk reseptoragonist- og muskarin reseptoragonistaktivitet | |
| NO20063597L (no) | Acetylinske piperazinforbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister | |
| MX2020009062A (es) | Piperidinil-3-(ariloxi)propanamidas y propanoatos. | |
| MXPA04002338A (es) | Derivados de carbazol y su uso como antagonistas receptores del npy5. | |
| ATE473961T1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
| NO20076060L (no) | Piperidin-4-yl-amidderivater og deres anvendelse som SST-reseptor subtype 5-antagonister | |
| MY169274A (en) | Fused, tricyclic sulfonamide inhibitors of gamma secretase | |
| MX2010002576A (es) | Compuestos que contienen guanidina, utiles como antagonistas de los receptores muscarinicos. | |
| EA200601194A1 (ru) | Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором | |
| WO2021012049A8 (en) | Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors | |
| JOP20220063A1 (ar) | مشتقات بيريدازين-3(2h)-أون ملتحمة بأزول | |
| MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
| CR20220299A (es) | Derivados de becimidazol | |
| MX2021013135A (es) | Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2. | |
| MX2023009285A (es) | Compuestos novedosos. | |
| NO20080669L (no) | Acetylenpiperaziner som metabotrofiske glutamatreseptorantagonister | |
| NO20080671L (no) | Bisykliske piperaziner som metabotrofiske glutamatreseptorantagonister | |
| ATE523488T1 (de) | Histamin-h3-rezeptor-mittel, deren herstellung und therapeutische verwendung |